Schizophrenia is a highly debilitating condition and people with schizophrenia suffer from great disability. Lurasidone (trade name: Latuda), works by balancing the levels of dopamine and serotonin in your brain, substances that help regulate mood, behaviors, and thoughts. Lurasidone belongs to a group of medications called antipsychotics. Antipsychotic medications can be used to treat several kinds of mental health conditions, such as schizophrenia.

We are looking for consumer input on a Cochrane review that aimed to find out if lurasidone helps people with schizophrenia. The protocol was published in 2016: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012429/full.

Cochrane considers a consumer, in this case, to be a carer of somebody with schizophrenia, or who has taken part in the shared decision-making for somebody with schizophrenia. For consumer peer review, we will ask you to complete a short form with your feedback to ensure the review is accessible and relevant so that it will be helpful to patients and their carers/families with healthcare decision-making.

You are welcome to provide feedback on any aspect of the review, or you can focus your attention on the sections you feel are most relevant to consumers and stakeholders, such as Abstract, Plain Language Summary, and Conclusions. Our aim is for this to be a manageable task, that does not overburden consumer reviewers.

Thank you in advance for considering!